EFTA Document EFTA01462612

Subject: S/Y and Biotech IC From: Tazia Smith < Date: Wed, 23 Apr 2014 11:54:04 -0400 To: eevacatione•mail.com Cc: Paul Morris Nav Gupta Vinit Sahni < Vahe Stepanian Classification: Confidential Jeffrey - Just posting you on your biotech basket - earnings a positive catalyst reversing that downtrend in G ilead. Biogen reported this morning (bottom line miss, top-line beat), stock has come in from pre-ma rket highs of $310, now -$303 (3-day chart below). Just a reminder that your SY 102.5 call is going to expire 5/1. In speaking with Nav and Vinit, the y looked at lot of weaker-yen iterations but their view is vols are too low and there is an absence of catalysts to present a compelling trade at this moment to roll into; Nav will email you directly to highlight entry points on a trade when he sees one. As you know, you've got your zero-cost optio n on for some exposure to yen weakness. (Embedded image moved to file: pic25012.gif)Source: Pershing, LLC and Bloomberg (Embedded image moved to file: pic20056.gif) Biogen - 3-day inter-day chart (Embedded image moved to file: pic27955.gif) (Embedded image moved to file: pic15934.gif) Tazia Smith Director I Key Client Partners - US DB Securities Inc Deutsche Asset & Wealth Management 345 Park Avenue 10154-0004 New York, NY, USA Tel. Fax Mobile Email (Embedded image moved to file: pic28276.gif) EFTA01462612